Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic cholestatic liver diseases. However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose UDCA in patients with primary sclerosing cholangitis (PSC) may be harmful; adverse events, such as death and liver transplantation, were significantly higher in patients who received UDCA compared with placebo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maggs, J. R. & Chapman, R. W. An update on primary sclerosing cholangitis. Curr. Opin. Gastroenterol. 24, 377–383 (2008).
Chapman, R. W. High dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Throwing the urso out with the bathwater? Hepatology 50, 671–673 (2009).
Lindor, K. D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336, 691–695 (1997).
Olsson, R. et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129, 1464–1472 (2005).
Cullen, S. N. et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J. Hepatol. 48, 792–800 (2008).
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F. & Lindor, K. D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 96, 1558–1562 (2001).
Lindor, K. D. et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50, 808–814 (2009).
Fickert, P. et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123, 1238–1251 (2002).
Rodriques, C. M., Fan, G., Ma, X., Kren, B. T. & Steer, C. J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. 101, 2790–2799 (1998).
Halilbasic, E. et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr-/-mice. Hepatology 49, 1972–1982 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Chapman, R. What is the role of ursodeoxycholic acid in therapy for PSC?. Nat Rev Gastroenterol Hepatol 7, 74–75 (2010). https://doi.org/10.1038/nrgastro.2009.235
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.235
